Biovie.
French company founded in 2007, specializing in online sales of organic, raw, and living foods, committed to education on healthy eating.
- Reports this week
- 0
- Active events
- 0
- Connections
- 35
What's happening
Earlier this month
-
Biovie discussed Phase 2 results for its bezisterim treatment and ongoing development of new antibiotics for difficult infections.Some support2 reports
-
BioVie's candidate outperformed findings from an initiative led by the National Institutes of Health.Some support1 report
-
BioVie is seeking pivotal milestones for its lead drug candidate targeting neuroinflammation pathways for Parkinson's disease.Well supported3 reports
One to three months ago
-
BioVie Inc., led by Cuong Do, is listed on Nasdaq, while First Phosphate, led by Passalacqua, is building a North American supply chain with European interest.Some support1 report
-
BioVie Inc. shares are traded on Nasdaq, and MarketBeat reported its average stock rating.Well supported6 reports1 development inside
-
MarketBeat's screener tool lists BioVie as a penny stock.Some support1 report
-
Biovie submitted trial data to the U.S. Food and Drug Administration and announced results from its offices in Carson City, Nev.Some support2 reports
Gone quiet
No new reports in 90+ days-
BioVie is testing a drug candidate called bezisterim for Long COVID and has received funding from the U.S. Department of Defense.Some support1 report
-
Mark Stacy was listed as an author on a clinical trial poster for Biovie.Speculative1 report
-
Biovie presented data at a conference held in Rome on July 24, 2025.Some support2 reports
-
Cuong Do was named CEO of Biovie, while FLOKI debuted a commercial broadcast by Bloomberg Television.Some support3 reports
-
Vision Marine Technologies Inc. filed a registration statement with the SEC, with ThinkEquity acting as the sole book-running manager.Some support3 reports
-
CDC reported that 6.9% of U.S. adults have long COVID, and the ADDRESS-LC trial is enrolling patients.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Biovie this week
News at the entities that move Biovie most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Biovie
-
MarketBeat Mentioned togetherApple Inc. stock is traded on Nasdaq, and Jefferies Financial Group restated a hold rating on the company.Moves Biovie
-
Renaissance Technologies TransactionalRenaissance Technologies holds a significant stake in Lite Strategy, Inc., whose stock trades on the Nasdaq exchange.Moves Biovie
-
National Institutes of Health OperationalPDS Biotechnology and the National Cancer Institute entered into a collaborative R&D agreement.Moves Biovie
-
Nasdaq StructuralAppLovin stock is traded on Nasdaq, and both AppLovin and Trade Desk operate in the competitive digital advertising technology landscape.Moves Biovie
-
Bloomberg Television OperationalStephen Chiu serves as chief emerging markets FX strategist for Bloomberg Television, analyzing market resilience in bond markets.Moves Biovie
Connections
The 13 strongest of 35, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Cuong Do Structural
Cuong Do holds the executive leadership role of President and CEO at Biovie.
-
Nasdaq Structural
Biovie Inc. is a company whose shares are formally listed and traded on the Nasdaq stock exchange.
-
FDA Structural
Biovie relies on the FDA's regulatory review process for drug development and seeking approval.
-
Mark Stacy Operational
Mark Stacy is a professional contributor whose expertise is featured in company trials and presentations for Biovie.
-
MarketBeat Mentioned together
MarketBeat tracks and reports on Biovie's market status, and Biovie utilizes MarketBeat's consensus rating data.
-
Bloomberg Television Operational
Biovie leverages Bloomberg Television as a platform to broadcast its innovations and clinical results.
-
National Institutes of Health Operational
Biovie's candidate was evaluated against and found to outperform findings from the NIH initiative.
-
Renaissance Technologies Transactional
Renaissance Technologies increased its financial holdings in BioVie stock.
Show all 13 connections
-
phase Operational
Biovie is actively conducting a Phase IIb clinical trial.
-
New York City Shared context
Biovie conducts professional activities and broadcasts while located in New York City.
-
San Francisco Shared context
The company is contextually linked to the city through the presence of associated medical professionals.
-
North America Shared context
Biovie conducts clinical trials and advances its pipeline within the North American market context.
-
Carson City Shared context
Biovie maintains offices in Carson City, Nevada.
History
Events by the month they beganSeptember 2026
2 eventsAugust 2026
3 events- BioVie Inc., led by Cuong Do, is listed on Nasdaq, while First Phosphate, led by Passalacqua, is building a North American supply chain with European interest.
- MarketBeat's screener tool lists BioVie as a penny stock.
- Biovie submitted trial data to the U.S. Food and Drug Administration and announced results from its offices in Carson City, Nev.
June 2026
8 events- BioVie is seeking pivotal milestones for its lead drug candidate targeting neuroinflammation pathways for Parkinson's disease.
- BioVie Inc. shares are traded on Nasdaq, and MarketBeat reported its average stock rating.
- BioVie is testing a drug candidate called bezisterim for Long COVID and has received funding from the U.S. Department of Defense.
- Mark Stacy was listed as an author on a clinical trial poster for Biovie.
- Biovie presented data at a conference held in Rome on July 24, 2025.
- Cuong Do was named CEO of Biovie, while FLOKI debuted a commercial broadcast by Bloomberg Television.
- Vision Marine Technologies Inc. filed a registration statement with the SEC, with ThinkEquity acting as the sole book-running manager.
- CDC reported that 6.9% of U.S. adults have long COVID, and the ADDRESS-LC trial is enrolling patients.